CAR-T

Alongside industry professionals interested in the cell and gene therapy landscape in Europe, DDW’s Multimedia Editor Megan Thomas was welcomed to Advanced Therapies Europe 2022 by Phacilitate’s Vice President, Becky Johnson-Kent. Johnson-Kent introduced the notion of the zebra company and compared its two-fold purpose of profitability and societal advancement to the cell and gene therapy industry. […]

The European Commission (EC) has approved biotechnology company Kite’s CAR T-cell therapy Yescarta for patients with follicular lymphoma (FL).  Specifically the approval is for adult patients with relapsed or refractory follicular lymphoma (FL) after three or more lines of systemic therapy.  The approval was based on data from the ongoing single-arm Phase II  ZUME-5 study […]

News round-up by DDW’s Reece Armstrong for 6-10 June Antibiotic developments, vaccines for MMR and business expansions are some of the features of this week’s news round-up. US gets another MMR vaccine option in GSK’s Priorix   GSK’s vaccine for the prevention of measles, mumps and rubella (MMR) has been approved by the US FDA, the […]

Biopharmaceutical company Kite has announced long-term follow up results of two studies for its CAR T-cell therapy Tecartus (brexucabtagene autoleucel). The results of both a three- and two-year follow-up of the company’s ZUMA trial were announced at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting.  The announcement included the three-year follow-up of ZUMA-2, a […]

This guide examines how cell and gene therapy transform cancer treatment. While cell therapies like CAR-T are promising cancer treatments, many challenges remain, including improving responses in blood cancers and efficacy in solid tumours. This new cancer therapy guide from 10x Genomics will outline: Cutting-edge single cell and spatial analysis technologies to unlock molecular insights The discovery of targets […]

A study from researchers in the Perelman School of Medicine at the University of Pennsylvania has shown that an experimental immunotherapy can temporarily reprogramme patients’ immune cells to attack a specific target via only a single injection of mRNA, similar to the mRNA-based Covid-19 vaccines.  Context  The researchers, whose work is published in Science, demonstrated the new approach with an […]

Janssen Pharmaceutical has recently filed for B-cell maturation antigen (BCMA) CAR-T therapy Cilta-cel in Japan. Earlier in March 2021, Bristol-Myers Squibb (BMS) filed for the first BCMA CAR-T therapy idecabtagene vicleucel, in the country. Following approval by the Japanese regulatory authority, BMS will have the first-mover advantage. However, stiff competition is expected for multiple myeloma treatment in the […]

Chimeric Antigen Receptor or CAR-T cells, a new form of immunotherapy with genetically engineered immune system cells, has been approved for the treatment of multiple myeloma, a type of blood cancer.  Context  In a case study published in Nature Medicine, Sinai scientists reported a previously unknown neurological side effect resembling symptoms Parkinson’s Disease in a patient […]

In this free webinar, Dr. Christoph Herbel presents a newly developed workflow which combines flow cytometry–based screenings with high-parameter imaging to identify and validate new tumour markers in an unbiased approach.   The event, Kill the tumour, spare the healthy tissue. Ultra high-content imaging enables target discovery for CAR T cell therapy, was hosted by DDW and supported by Miltenyi Biotec.  It took place on 14 Dec, 4PM GMT, 5PM CET.  Watch on Demand […]

CAR T cell technology provides the foundation for established immunotherapies against certain types of blood cancer and holds great promise for the fight against many solid tumours too. One major drawback of conventional CAR T cell technology, which relies on a single target antigen, is the lack of tumour-associated antigens (TAAs) that are truly specific for cancer cells. […]